CoChat
Sign Up
Cited by 44HIV-related health complications and treatmentsAdipokines, Inflammation, and Metabolic DiseasesHIV Research and Treatment

Adiponectin and HIV-Lipodystrophy: Taking HAART

Kinlaw, William B., Marsh, Bryan·2004·Endocrinology
DOI 10.1210/en.2003-1513
Open this paper in CoChat — free account

Abstract

Infection with HIV and consequent AIDS is a major public health problem affecting more than 40 million people worldwide. Successful combination therapy based on HIV protease inhibitors, reverse transcriptase inhibitors (both nucleoside analogs and nonnucleoside analogs), and fusion inhibitors, with the goal of complete suppression of viral replication and meaningful immune restoration [highly active antiretroviral therapy (HAART)], has improved the prognosis of patients to the point that long-term complications of treatment have become an important clinical concern. Such major complications that have emerged are metabolic and have been termed the “HIV-lipodystrophy syndrome,” although it is not clear that all of the described metabolic abnormalities are truly part of a single syndrome. These metabolic abnormalities were first associated with protease inhibitors, but both nonnucleoside analogs and at least one of the nucleoside analogs (stavudine) have also been implicated. The picture includes lipodystrophy, hypertriglyceride- and cholesterol-emia, and insulin resistance, with or without hyperglycemia (1, 2). This raises two major concerns. First is the specter of increased risk for cardiovascular disease, which could mitigate the prospect of longevity offered by HAART. Second is that cosmetic aspects as well as heightened concern about cardiovascular disease could impel patients to reject effective therapy. In this issue of Endocrinology, Xu et al. (3) describe a promising therapeutic approach in a mouse model of HIV-lipodystrophy.

Integrity signals

Registry

Crossref · 10.1210/en.2003-1513

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lipodystrophy is highly prevalent in patients on highly active antiretroviral therapy, occurring in 40% to 80% of patients.

    “Lipodystrophy, characterized by morphological (peripheral lipoatrophy, localized fat accumulation) and metabolic changes (hyperlipidemia, insulin resistance and hyperglycemia), is highly prevalent in patients on highly active antiretroviral therapy (HAART), occurring in 40% to 80% of patients [115].”

    From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [115]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Kinlaw, W. B., & Marsh, B.
Affiliations
Dartmouth College (US)
Corresponding author
Kinlaw, William B.
ORCID
Kinlaw, William B.
Venue
Endocrinology
Publisher
The Endocrine Society
Published
2004-02
Volume
145
Issue
2
Pages
484-486
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
DOI
10.1210/en.2003-1513
OpenAlex
W2018963910
Cited by
44
References
32
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2022: 2 · 2020: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 3
FWCI
5.70
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
  • Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
adiponectin, highly active antiretroviral therapy, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, stavudine, lipodystrophy, insulin resistance, hypertriglyceridemia, dyslipidemia, hyperglycemia, cardiovascular risk, mouse model
MeSH terms
Acquired Immunodeficiency Syndrome, Animals, Cardiovascular Diseases, DNA-Binding Proteins, Humans, Insulin Resistance, Proteins, Transcription Factors, CCAAT-Enhancer-Binding Proteins, Antiretroviral Therapy, Highly Active, Intercellular Signaling Peptides and Proteins, HIV-Associated Lipodystrophy Syndrome, Mice, Sterol Regulatory Element Binding Protein 1, Adiponectin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review